Ofev
nintedanib
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Ofev. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Ofev.
For practical information about using Ofev, patients should read the package leaflet or contact their doctor or pharmacist.
-
List item
Ofev : EPAR - Summary for the public (PDF/68.46 KB)
First published: 13/02/2015
Last updated: 13/02/2015
EMA/724832/2014 -
-
List item
Ofev : EPAR - Risk-management-plan summary (PDF/121.7 KB)
First published: 13/02/2015
Last updated: 27/11/2018
Page 1/6
Authorisation details
Product details | |
---|---|
Name |
Ofev
|
Agency product number |
EMEA/H/C/003821
|
Active substance |
nintedanib
|
International non-proprietary name (INN) or common name |
nintedanib
|
Therapeutic area (MeSH) |
Idiopathic Pulmonary Fibrosis
|
Anatomical therapeutic chemical (ATC) code |
L01XE
|
Additional monitoring |
This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring. |
Orphan |
This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation. |
Publication details | |
---|---|
Marketing-authorisation holder |
Boehringer Ingelheim International GmbH
|
Revision |
9
|
Date of issue of marketing authorisation valid throughout the European Union |
14/01/2015
|
Contact address |
Product information
31/10/2018 Ofev - EMEA/H/C/003821 - II/0021
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Antineoplastic agents
Therapeutic indication
Ofev is indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF).